NCI requests $7.8B for FY2023 to increase R01 paylines to 13th percentile

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI is asking for an appropriation of $7.8 billion for fiscal year 2023—about $800 million above the House’s FY22 proposed budget for NCI.

This amount, specified by the institute’s Bypass Budget, is calibrated toward raising paylines to the 15th percentile by 2025. 

“Several years ago, we started a concerted effort to raise the payline to the 15th percentile by 2025,” Sharpless said Sept. 1 in his remarks to the National Cancer Advisory Board. “That is the ‘15-by-25’ initiative, and robust and sustained investments are needed to achieve that level.”

As it stands, NCI paylines are at the 11th percentile, and the success rate for investigator-initiated research project grants is 12.8%.

The Bypass Budget, also known as the Professional Judgment Budget, is one of the unique authorities given to NCI under the National Cancer Act of 1971. The law allows the institute director to bypass budget review at NIH and HHS and submit this request directly to the White House. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, and her research team have received a five-year, $3.9 million grant from NCI to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer. 
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login